The images below were selected from a 153 page PDF linked the GreatGameIndia.com's article:
The PDF linked to the article is more legible on the website than the images I copied below.
I placed my own notes or links at the top of this post and the images of the document at the bottom.
I skimmed the document and copied pages of interest to me. Sometimes I copied pages simply to capture signatures. In a few places, I included reference links
Page 44 listed the following shipment from ModernaTX, Inc. to NIAID.
Sera from B/6 mice that have been vaccinated with Provider's investigated zika virus vaccine [proprietary info] (5 placebo samples and 5 active samples).
Page 61 listed viral strains provided by NIAID to Moderna. As the text was barely legible, I obtained identifying links specified in the table and placed them below the captured images for page 61.
I included the following Wiki link below the first instance in which I noticed the document referred to BARDA funded research:
Biomedical Advanced Research and Development Authority - Wikipedia
Excerpt of page 80: "The Vaccine Research Center, NIAID ("VRC/NIAID") has extensive experience with the development of vaccines against infectious diseases and structure-based design of vaccine candidates. I particular, VRC/NIAID has developed stabilized prefusion MERS-CoV spike protein, which is more immunogenic than wild-type or subunit proteins. This stabilized prefusion protein is currently being evaluated in preclinical studies. Based on the VRC's prior experience stabilizing the fusion (F) protein in it's prefusion conformation with the related respiractory syncytial virus and parainfluenza virus 3 (PIV3), the VRC has designed stabilized Npiah F proteins which are currently being evaluated in preclinical studies."
Immunogenic | Definition of Immunogenic by Merriam-Webster
Middle East respiratory syndrome coronavirus (MERS-CoV) (who.int)
Page 86 listed cell lines the NIAID would provide to Moderna. As the text was barely legible, I obtained identifying links specified in the table and placed them below the captured images for page 86.
Page 101 listed cell lines and virus samples the NIAID would provide to Moderna.
Page 105 listed shipment from NIAID to University of North Carolina at ChapelHill the following materials:
"mRNA coronavirus vaccine candidates developed and jointly-owned by NIAID and Moderna."
The stated purpose of the use of these materials is as follows.
"Perform challenge studies with the mRNA vaccine in a [proprietary info] model as described on Exhibit A."
[ransomnote: Exhibit A content on page 109 is redacted.]
Page 111 contains two license numbers and a list of patents.
Page 115 contained redacted NIAID licensing and royalties information [ransomnote: Was Wuhan, China on that redacted list?]
Page 123 contains a list of patents and patent applications
Page 124 contains a list of licensed products.
Page 125 contains Appendix C, a redacted description of royalties received by NIAID.
Page 126 is ModernaTX shipping contact Samantha Calabrese
Page 127 - 128 royalty payment options
Page 134 - 136 royalty payment information
Page 138 -147 NAID License Agreement with ModernaTX, Inc - Zika vaccine
Page 148 List of (2) Patent applications - Zika vaccine
Page 149 (image below) list of tangible patent materials.
Page 150 - 153 royalty payments
~~~~Document begins~~~~
[ransomnote: above is 5 of 153]
[ransomnote: above is 6 of 153]
[ransomnote: above is 9 of 153]
[ransomnote: above is 10 of 153]
[ransomnote: above is 11 of 153]
[ransomnote: above is 12 of 153]
[ransomnote: above is 13 of 153]
[ransomnote: above is 14 of 153]
[ransomnote: above is 15 of 153]
[ransomnote: above is 19 of 153]
[ransomnote: above is 28 of 153]
[ransomnote: above is 29 of 153]
[ransomnote: above is 35 of 153]
[ransomnote: above is 36 of 153]
[ransomnote: above is 37 of 153]
[ransomnote: above is 38 of 153]
[ransomnote: above is 39 of 153]
[ransomnote: above is 40 of 153]
[ransomnote: above is 41 of 153]
[ransomnote: above is 42 of 153]
[ransomnote: above is 43 of 153]
[ransomnote: above is 44 of 153]
[ransomnote: above is 47 of 153]
[ransomnote: above is 54 of 153]
[ransomnote: above is 55 of 153]
[ransomnote: above is 56 of 153]
[ransomnote: above is 58 of 153]
[ransomnote: above is 59 of 153]
A shipment from NIAID to Moderna:
[ransomnote: above is 61 of 153]
[ransomnote: above is 64 of 153]
Biomedical Advanced Research and Development Authority - Wikipedia
[ransomnote: above is 65 of 153]
[ransomnote: above is 66 of 153]
[ransomnote: above is 67 of 153]
[ransomnote: above is 74 of 153]
[ransomnote: above is 79 of 153]
Excerpt of page 80: "The Vaccine Research Center, NIAID ("VRC/NIAID") has extensive experience with the development of vaccines against infectious diseases and structure-based design of vaccine candidates. I particular, VRC/NIAID has developed stabilized prefusion MERS-CoV spike protein, which is more immunogenic than wild-type or subunit proteins. This stabilized prefusion protein is currently being evaluated in preclinical studies. Based on the VRC's prior experience stabilizing the fusion (F) protein in it's prefusion conformation with the related respiractory syncytial virus and parainfluenza virus 3 (PIV3), the VRC has designed stabilized Npiah F proteins which are currently being evaluated in preclinical studies."
Immunogenic | Definition of Immunogenic by Merriam-Webster
Middle East respiratory syndrome coronavirus (MERS-CoV) (who.int)
[ransomnote: above is 80 of 153]
[ransomnote: above is 85 of 153]
As the text was barely legible, I obtained links specified in the table and placed them below the captured images for page 86.
[ransomnote: above is 86 of 153]
[ransomnote: above is 89 of 153]
A shipment from NIAID to Moderna:
[ransomnote: above is 101 of 153]
Shipment from NIAID to University of North Carolina at ChapelHill the following materials:
"mRNA coronavirus vaccine candidates developed and jointly-owned by NIAID and Moderna."
The stated purpose of the use of these materials is as follows.
"Perform challenge studies with the mRNA vaccine in a [proprietary info] model as described on Exhibit A."
ransomnote: Exhibit A content on page 109 is redacted.
[ransomnote: above is 105 of 153]
[ransomnote: above is 107 of 153]
[ransomnote: above is 108 of 153]
[ransomnote: above is 110 of 153]
[ransomnote: above is 111 of 153]
[ransomnote: above is 121 of 153]
[ransomnote: above is 122 of 153]
[ransomnote: above is 123 of 153]
[ransomnote: above is 124 of 153]
[ransomnote: above is 149 of 153]